Mr. Manish Pungliya


AyuGen Biosciences Pvt Ltd


Pune, Maharashtra


Our product (test) target women from age group of 25 and above. As we know cervical cancer is the second most common cancer affecting women in India. This is the only cancer whose cause is now known and proven preventive measure are available. Still daily over 180 women die of cervical cancer in India. All the women of the age 30 years and above are the direct beneficiaries of this test.


Our test is a screening test that help in identifying women at-risk of cervical cancer (even before they get cancer). The test has a very high negative predictive value (99.9%) and is twice more accurate than currently available methods (pap smear or VIA). Moreover, If negative it is required to be done once in 5 to 10 years. Currently we received samples from across India using logistic services of the commercial logistic company. We process about 500 samples a month.

Scalability and Impact:

We want to screen at least 5 lakh women in three years and bring down the incidence of CaCx significantly. Our data over 15000 women shows variable incidences of presence of virus that causes cervical cancer – be it urban rural or tribal. We have done multiple projects with NGOs and CSRs for the rural and tribal populations.

Financial Requirements:


Awards and Recognition:

Our company received prestigious ASSOCHAM award at the hand of Health Minister in 2018 as Outstanding Cervical Cancer Diagnostic Laboratory in India. Our lab is NABL accredited since 2013.
Scroll to Top